Rénibus Therapeutics Inc. (RTI)
is a clinical-stage biotech company focused on the development of novel pharmacologic therapies for acute and chronic kidney disease. Acute Kidney Injury (AKI) remains a significant, unmet medical need with no approved treatment. Postoperative AKI occurs in approximately 30% of patients undergoing cardiac surgery and significantly increases the risk of death (Rosner 2006). Progression to chr...
Rénibus Therapeutics Inc. (RTI)
is a clinical-stage biotech company focused on the development of novel pharmacologic therapies for acute and chronic kidney disease. Acute Kidney Injury (AKI) remains a significant, unmet medical need with no approved treatment. Postoperative AKI occurs in approximately 30% of patients undergoing cardiac surgery and significantly increases the risk of death (Rosner 2006). Progression to chronic kidney disease (CKD) within 24 months occurs in approximately 15-20% of patients who survive AKI (Chawla 2012).
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.